Graft versus host disease (GVHD) - Pipeline Insight, 2022

DelveInsight's, Graft versus host disease (GVHD) - Pipeline Insight, 2022," report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Graft versus host disease (GVHD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Graft versus host disease (GVHD) Understanding

Graft versus host disease (GVHD): Overview

Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient's body cells. "Graft" refers to transplanted, or donated tissue, and "host" refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT) [1].

Cells of the immune system are trained early to differentiate between "self" cells and "non-self" cells. The ability to recognize "non-self" cells depends on a set of genes knows as the histocompatibility genes that provide instructions for making a group of related proteins known as major histocompatibility complex (MHC proteins) or human leukocyte antigens (HLA).

"Graft versus host disease (GVHD) - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graft versus host disease (GVHD) pipeline landscape is provided which includes the disease overview and Graft versus host disease (GVHD) treatment guidelines. The assessment part of the report embraces, in depth Graft versus host disease (GVHD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graft versus host disease (GVHD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Graft versus host disease (GVHD). The therapies under development are focused on novel approaches to treat/improve Graft versus host disease (GVHD).

Graft versus host disease (GVHD) Emerging Drugs

Teplizumab: Prevention Bio

MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, Microbiome Ecosystem Therapy. It is characterized by a consistently high diversity and richness of microbial species and the presence of ButycoreTM (group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient's functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

ASC930: ASC Therapeutics

ASC930 is an allogeneic cell therapy based on off-the-shelf Decidua Stromal Cells obtained from the fetal membrane of the maternal placenta for the treatment of acute steroid-refractory Graft-versus-Host Disease, a common complication of patients receiving allogeneic hematopoietic stem cell transplantation to treat hematologic conditions. ASC930 cells possess potent immunosuppressive properties and do not display any differentiation potential, making them an ideal immunoregulatory cell therapy.

Further product details are provided in the report……..

Graft versus host disease (GVHD): Therapeutic Assessment

This segment of the report provides insights about the Graft versus host disease (GVHD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Graft versus host disease (GVHD)

There are approx. 60+ key companies which are developing the therapies Graft versus host disease (GVHD). The companies which have their Graft versus host disease (GVHD) drug candidates in the most advanced stage, i.e preregistration include ElsaLys Biotech

• Phases

DelveInsight's report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Graft versus host disease (GVHD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Graft versus host disease (GVHD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Graft versus host disease (GVHD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Graft versus host disease (GVHD) drugs.

Graft versus host disease (GVHD) Report Insights

• Graft versus host disease (GVHD) Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Graft versus host disease (GVHD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Graft versus host disease (GVHD) drugs?
• How many Graft versus host disease (GVHD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Graft versus host disease (GVHD)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Graft versus host disease (GVHD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Graft versus host disease (GVHD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biocon
• medac GmbH
• MaaT Pharma
• ElsaLys Biotech
• Glia
• Syndax Pharmaceuticals
• ASC Therapeutics
• SCM Lifescience
• REGiMMUNE
• Roche
• VectivBio
• Chia Tai Tianqing Pharmaceutical Group
• Amgen
• Pfizer
• Plexxikon
• Medsenic
• Xenothera

Key Products

• Itolizumab
• MC 0518
• MaaT013
• Inolimomab
• PG101
• Axatilimab
• ASC930
• SCM CGH
• Alpha galactosylceramide liposomal
• Obinutuzumab
• Apraglutide
• TQ 05105
• Efavaleukin alfa
• Glasdegib
• PLX 51107
• Arsenic trioxide
• LIS1
• TQ 05105